Photo taken from Hidehito Horinouchi/X
Sep 27, 2023, 16:57
Hidehito Horinouchi: Reconsidering the cutoff for sensitive and refractory relapses in ES-SCLC in the era of ICIs in JTO and JTO CRR by Dr. Masahiro Torasawa.
Hidehito Horinouchi, Assistant Chief of the Department of Thoracic Oncology at National Cancer Center Hospital, shared a post on Twitter:
“JUST ACCEPTED: Reconsidering the cutoff for sensitive and refractory relapses in ES-SCLC in the era of ICIs in JTO and JTO CRR by Dr. Masahiro Torasawa. The 75-day cutoff most accurately predicts subsequent prognosis.
Abstract 8576: Reconsidering the cutoff between sensitive and refractory relapses in ES-SCLC in the era of immunotherapy by Dr. Masahiro Torasawa. The optimal cutoff value is 75 days. Traditional cutoff (60 or 90 days) remains valid as well.
For the articles attached to the post click here and here.”
Source: Hidehito Horinouchi/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 14:06
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33